FYU 981

Drug Profile

FYU 981

Alternative Names: FYU-981

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Fuji Yakuhin
  • Class Uricosurics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Hyperuricaemia

Most Recent Events

  • 28 Nov 2017 Mochida Pharmaceutical in collaboration with Fuji Yakuhin plans a phase I drug-drug interaction study of FYU 981 and oxaprozin (In Volunteers) in Japan in November 2017 (NCT03350386)
  • 22 Nov 2017 Mochida Pharmaceutical plans a phase I pharmacokinetics trial in Healthy volunteers in Japan in November 2017 (NCT03350373)
  • 13 Oct 2017 Fuji Yakuhin and Mochida Pharmaceutical Company plans a phase I trial for Liver-cirrhosis (In volunteers) in Japan (PO) in October 2017 (NCT03306667)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top